Treatment

Findings show that combining abemaciclib (Verzenio) with letrozole is an effective treatment for advanced or recurrent endometrial cancer. The study found strong disease control, especially in patients who had not previously received chemotherapy. Overall, 56.9% of patients were progression-free at 6 months, rising to 71.4% in chemo-naïve patients. The median progression-free survival was 9.5 months […]

Managing extensive-stage small cell lung cancer (ES-SCLC) involves not only treating the cancer aggressively but also preventing chemotherapy-induced myelosuppression, a dangerous drop in blood cell counts that can lead to infections like febrile neutropenia. One common strategy is the use of granulocyte colony-stimulating factor (G-CSF), which helps the body produce more neutrophils. It is often

The U.S. Food and Drug Administration granted full approval to brexucabtagene autoleucel (Tecartus), a CAR T-cell therapy for relapsed or refractory mantle cell lymphoma (MCL), marking a major advance in treatment. According to Lore Gruenbaum of Blood Cancer United, the approval also raises new questions about how best to use this powerful therapy. The decision

Results from the Phase 3 PRESERVE-003 trial show that the immunotherapy gotistobart significantly outperforms standard chemotherapy in patients with previously treated advanced squamous non-small cell lung cancer. Compared to docetaxel, gotistobart reduced the risk of death by 54% and more than doubled the 12-month survival rate (63.1% vs. 30.3%). Median overall survival has not yet

Researchers have identified a new small-molecule drug, UNC569, as a promising therapy for pancreatic ductal adenocarcinoma (PDAC), one of the deadliest and most treatment-resistant cancers. UNC569 targets the MerTK receptor, which helps cancer cells survive and spread, triggering cancer cell death and overcoming drug resistance. The drug works through a “two-pronged” mechanism. First, it induces

A study shows that a reduced-dose conditioning regimen can make tumor-infiltrating lymphocyte (TIL) therapy safer and more tolerable for older or frail patients with metastatic melanoma. Researchers cut the cyclophosphamide dose in half while keeping fludarabine at the standard level. Seventeen high-risk patients, aged 66–78, were treated, many with brain metastases or other health issues.

Nuvalent has submitted a New Drug Application (NDA) to the FDA for neladalkib (NVL-655), an ALK-targeted therapy for advanced ALK-positive non–small cell lung cancer (NSCLC) in patients previously treated with tyrosine kinase inhibitors (TKIs). The submission is based on the Phase 1/2 ALKOVE-1 trial, which included patients treated with lorlatinib or chemotherapy. The trial showed

Researchers have developed a new experimental nanotherapy that shows strong potential against glioblastoma, one of the most aggressive brain cancers. The treatment uses tiny lipid-based particles called liposomes that can cross the blood-brain barrier. These particles deliver two drugs—everolimus (or rapamycin) and vinorelbine—directly into tumor cells at the same time. In preclinical studies, combining this

A new Phase 1b study shows that combining the novel T-cell therapy pasritamig with docetaxel produces high response rates in patients with metastatic castration-resistant prostate cancer (mCRPC). Patients receiving the combination saw PSA reductions far exceeding typical results with chemotherapy alone. About 65% achieved a 50% drop in PSA levels, and rates rose to 88%

A new study shows that high-dose “ablative” radiation can greatly improve outcomes for patients with large bile duct cancers, including tumors bigger than 10 cm. Researchers found that patients who received this precise, high-dose radiation along with chemotherapy lived much longer—about 28.7 months on average—compared to 11.9 months for those treated with chemotherapy alone. The